5/24/2022 3:07:37 AM
Lilly: 50% Of Patients With UC Treated With Mirikizumab Achieved Clinical Remission At 1 Yr In Phase 3 Study
5/20/2022 8:19:00 AM
Lilly : CHMP Issues Positive Opinion For OLUMIANT For Treatment Of Adults With Severe Alopecia Areata
5/11/2022 6:51:49 AM
Lilly And Incyte: FDA Approves OLUMIANT For Certain Hospitalized Patients With COVID-19
5/6/2022 3:00:17 PM
Eli Lilly And Co. Elects Mary Lynne Hedley To Board Of Directors
5/2/2022 4:02:01 PM
Lilly Declares Q2 Dividend Of $0.98/share, Payable June 10/ Record May 16
5/2/2022 3:40:09 PM
Eli Lilly And Co. (LLY) Declares $ 0.98 Dividend for Q2 22, Record Date 5/16/2022
4/28/2022 6:33:10 AM
Eli Lilly And Co. (LLY) Has Lowered Its FY22 EPS Estimate To 8.15 - 8.30 From 8.50 - 8.65
4/28/2022 6:32:11 AM
Eli Lilly And Co. (LLY) Has Raised Its FY22 Revenue Estimate To $28.8 to $29.3 Bln From $27.8 to $28.3 Bln
4/28/2022 6:26:43 AM
Lilly Q1 EPS Up 41% To $2.10 On Reported Basis And Up 63% To $2.62 On Non-GAAP Basis
4/28/2022 6:17:15 AM
Lilly Says Tirzepatide Delivered Up To 22.5% Weight Loss In Adults With Obesity Or Overweight In SURMOUNT-1